Ability of splenocytes from tumor-bearing mice treated with AdmCD40L-modified DCs to transfer tumor-specific immunity.
(A) Splenocytes from mice with CT26 tumors treated with AdmCD40L-infected DCs. The 8-day established subcutaneous CT26 tumors in Balb/c mice were inoculated with 2 × 105 DCs modified with AdmCD40L (▪) or AdNull (□) at moi of 40 for 24 hours. Ten days after administration, splenocytes were transferred intravenously to naive recipients (5 × 107 cells per mouse). Controls included mice without any infusion of splenocytes (Δ). Recipient mice were challenged 7 days later with subcutaneous administration of 2 × 105 CT26 cells (day 0). (B) Splenocytes from C57Bl/6 mice with B16 tumors. The study was similar to that in panel A, but B16 established tumors in C57Bl/6 mice were inoculated with modified DCs and recipient mice were challenged with 5 × 105 B16 cells. In both panels, survival was recorded as the percentage of surviving animals (Kaplan-Meir analysis,P < .05 AdmCD40L compared with all other groups).
